Holmusk, a behavioral health data analytics company, has raised $45 million in a Series B funding round led by Veradigm (formerly Allscripts Healthcare Solutions). The round also included participation from his existing investors Heritas Capital, Health Catalyst Capital, Novartis and Northwell Holdings.
Purpose
The Singapore- and New York-based company will use the new funding to continue expanding its NeuroBlu database, which has become one of the leading sources of real-world clinical data for the behavioral health industry.
Meanwhile, Veradigm plans to sign a data partnership with Holmusk to bring a cohort of de-identified patient data related to behavioral health into Holmusk’s database.
the bigger trend
Over the past two years, Holmusk has established multiple partnerships with hospitals and medical research institutions around the world to help advance behavioral health research while growing the NeuroBlu platform.It has an existing collaboration in the US Otsuka, University of Texas Health Science Center and Harris Center for Mental Health and IDDWhen metro care service; of National Healthcare Group and Institute of Mental Health in singapore.When Charité University Medical Faculty Berlin into German.
On the other hand, Veradigm’s investment in Holmusk rebrandingThe company is currently in a market that is moving from disparate to interoperable systems that can drive growth and transform medical data into actionable insights and support higher quality care. claims to be “well-positioned” to serve
on record
“This investment will allow our team to continue our data curation and enrichment work as we plan to build the world’s largest platform for behavioral health data. We continue to focus on this mission because we know it will lead to better health,” said Holmusk CEO and Founder Nawal Roy.
Veradigm CEO Rick Poulton commented:
